Stay updated on SB414 PK, PD, Safety in Psoriasis Clinical Trial
Sign up to get notified when there's something new on the SB414 PK, PD, Safety in Psoriasis Clinical Trial page.

Latest updates to the SB414 PK, PD, Safety in Psoriasis Clinical Trial page
- Check5 days agoChange DetectedA centralized Locations section now lists Idaho, Texas, and Virginia as study sites, replacing the prior state-specific location subsections, and the page revision is updated to v3.3.3.SummaryDifference0.5%

- Check12 days agoNo Change Detected
- Check19 days agoNo Change Detected
- Check33 days agoChange DetectedThe top of the page now shows Revision: v3.3.2, replacing Revision: v3.2.0. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check40 days agoChange DetectedDeleted the government-funding notice about potential data delays and limited response times. The page no longer displays the operating-status disclaimer.SummaryDifference0.4%

- Check54 days agoChange DetectedThe page appears to retain core study details (conditions, eligibility criteria, interventions, outcomes, locations, and dates) with only cosmetic layout changes between screenshots. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%

- Check83 days agoChange Detected- Updated the page to include a government-operating-status notice and a new version tag (v3.2.0), replacing the old v3.1.0.SummaryDifference5%

- Check90 days agoChange DetectedAdded version label (v3.1.0); removed multiple drug-safety and regulatory sections (Drug Safety, Counterfeit Drugs, Pharmaceutical Preparations, Substandard Drugs, etc.). The net effect is a narrowing of content rather than expansion.SummaryDifference0.6%

Stay in the know with updates to SB414 PK, PD, Safety in Psoriasis Clinical Trial
Enter your email address, and we'll notify you when there's something new on the SB414 PK, PD, Safety in Psoriasis Clinical Trial page.